SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine

Tuesday, April 15, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

DUBLIN, Calif., April 14 SuperGen Inc.(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapiddevelopment and commercialization of therapies for solid tumors andhematological malignancies, today announced as part of a series ofpresentations at the 2008 AACR Annual Meeting that S-110, its DNAmethyltransferase inhibitor, improves in vivo efficacy of decitabine (AbstractNo. 2613).

Entitled, "Decitabine administered as a Dinucleotide prodrug increases itsin vivo efficacy due to enhanced drug delivery and stability," the posterhighlights data indicating that S-110 showed robust anti-tumor activity inprostate and cisplatin-resistant ovarian carcinoma xenograft models.Additionally, S-110 restored sensitivity to cisplatin in the ovarian cancermodel. Importantly, reduced toxicity was observed along with an increasedhalf-life compared to decitabine.

"S-110's increased half-life, reduced toxicity and improvement of efficacywhen compared to decitabine in its currently marketed formulations make it anattractive, next-generation hypomethylator for the treatment of hematoligicmalignancies," said Dr. James Manuso, SuperGen's President and CEO. "As wedevelop S-110 further, we will continue to explore its potential to enhancesolid tumors' sensitivity to standard chemotherapy agents, includingcisplatin. We look forward to advancing this promising candidate to clinicaltrials later this year or early next year."

Copies of the 2008 AACR Annual Meeting poster presentations will beavailable in the pipeline section of SuperGen's Web site

About SuperGen

Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical companydedicated to the discovery, rapid development and commercialization oftherapies for solid tumors and hematological malignancies. SuperGen isdeveloping a number of therapeutic anticancer products focused on kinase andcell signaling inhibitors and DNA methyltransferase inhibitors. For moreinformation about SuperGen, please visit

Forward-Looking Statements

This news release contains certain "forward-looking" statements within themeaning of the Private Securities Litigation Reform Act of 1995. Thesestatements are typically preceded by words such as "believes," "expects,""anticipates," "intends," "will," "may," "should," or similar expressions.These forward-looking statements are not guarantees of future performance andinvolve a number of risks and uncertainties that may cause actual results todiffer materially from the results discussed in these statements. Factorsthat might cause the company's results to differ materially from thoseexpressed or implied by such forward-looking statements include, but are notlimited to, the ability to discover, develop and move target compounds intoclinical development and other risks and uncertainties detailed from time totime in the company's filings with the Securities and Exchange Commissionincluding its most recently filed Form 10-Q and 10-K. SuperGen Inc. undertakesno duty to update any of these forward-looking statements to conform them toactual results.Contacts Timothy L. Enns Mary M. Vegh SuperGen Inc. SuperGen Inc. SVP, Corporate Communications & Business Manager, Investor Development Relations Tel: (925) 560-0100 Tel: (925) 560-2845 E-mail: E-mail:

SOURCE SuperGen Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store